Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Post-ASH 2021 MPN Highlights
28 January 2022 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in myeloproliferative neoplasms (MPNs) from ASH 2021
The Post-ASH 2021 MPN Highlights virtual workshop was held on 28 January 2022. The program covered the latest in MPNs and featured a series of short presentations from invited experts on selected abstracts from the 63rd ASH Annual Meeting with interactive panel discussions after each session.
Session 1: Science Advances in the MPN Field
Genetic, Cellular & Molecular Landscape of TP53-Mutated LT in MPN
Adam Mead University of Oxford, Oxford, United Kingdom
MPN Clonal Evolution Landscape and its Impact on Patients' Prognosis
Lin-Pierre Zhao St. Louis Hospital, Paris, France
Identifying Patients with PV at High-Risk for Venous Thrombosis
Alessandro Vannucchi University of Florence, Florence, Italy
Single-Cell Mutation Analysis in LT of MPNs
Alessandro Vannucchi University of Florence, Florence, Italy
Session 1 panel discussion
Session 2: Novel Therapies for MF
A Phase I/II Study of Tagraxofusp in R/R Myelofibrosis
Abdulraheem Yacoub University of Kansas Medical Center, Kansas City, KS, United States
Pelabresib Monotherapy in Patients with Myelofibrosis
Srdan Verstovsek The University of Texas MD Anderson Cancer Center, Houston, TX, United States
A Phase I Study: Treatment of Myelofibrosis Patients with AVID200
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
A Comparison of Pacritinib and Ruxolitinib
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Navtemadlin Activity in R/R Myelofibrosis
Pankit Vachhani The University of Alabama at Birmingham, Birmingham, AL, United States
Session 2 panel discussion
Session 3: Therapies for MPNs, Mastocytosis & MLNs
Updates from the Phase II PATHFINDER Study
Jason Gotlib Stanford University School of Medicine, Stanford, CA, United States
Bezuclastinib Treatment in Patients with Advanced Systemic Mastocytosis
Jason Gotlib Stanford University School of Medicine, Stanford, CA, United States
A Phase II Study of Pemigatinib in Patients with MLN FGFR1
Andreas Reiter University Medical Centre Mannheim, Mannheim, Germany
A Phase II Study: Bomedemstat in the Treatment of ET
Francesca Palandri Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Effects of Rusfertide in Patients with Polycythemia Vera
Srdan Verstovsek The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Reduced Intensity Stem Cell Transplantation for Accelerated-Phase MF
Nico Gagelmann University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Efficacy of HMA +/- Venetoclax or Chemotherapy in Blast-Phase MPNs
Kristen Pettit University of Michigan, Ann Arbor, MI, United States
Session 3 panel discussion
Session 4: Open Studies
ADORE Trial: Evaluating the Safety & Efficacy of Ruxolitinib in Patients with MF
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Updates from the Phase III INDEPENDENCE Study
Ruben Mesa Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, United States
SURPASS-ET Trial: Second-Line Therapies for Essential Thrombocythemia
Ruben Mesa Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, United States
A Phase III Study of add-on bomedemstat in Patients with Myelofibrosis
Abdulraheem Yacoub University of Kansas Medical Center, Kansas City, KS, United States
Imetelstat vs Best Available Therapy in Patients with Int-2 or High-Risk MF
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
PTG-300 in Patients with Polycythemia Vera
Srdan Verstovsek The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Ruxolitinib plus Parsaclisib in JAK- and PI3K- Inhibitor Treatment-naive MF
Abdulraheem Yacoub University of Kansas Medical Center, Kansas City, KS, United States
A Pilot Study of Elotuzumab in Myelofibrosis
Prithviraj Bose The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 4 panel discussion
Meeting Supporters:
Visit the MPN channel for the latest updates from leading experts
